Core Insights - Investors prioritize businesses that consistently generate profits, with net profit margin being a crucial metric for assessing profitability and operational effectiveness [1][2] Summary by Sections Net Profit Margin - Net profit margin is calculated as Net Profit divided by Sales multiplied by 100, indicating a company's efficiency in converting sales into actual profits [2] - A higher net profit margin reflects better operational strength and cost management, which is essential for rewarding stakeholders and attracting talent [2] Pros and Cons - Net profit margin provides clarity on a company's business model, including pricing policy and manufacturing efficiency, making it a preferred metric for investors [3] - Limitations include significant variations across industries and complications arising from different accounting treatments, particularly for non-cash expenses [3][4] Winning Strategy - A healthy net profit margin and solid earnings per share (EPS) growth are key elements sought in a business model [5] Screening Parameters - Criteria for screening include a net margin of at least 0%, positive percentage change in EPS, and a high broker rating indicating bullishness on the stock [6][7] Company Highlights - Great Lakes Dredge & Dock Corporation (GLDD) is the largest provider of dredging services in the U.S., with a Zacks Rank of 1 and a VGM Score of A, and its 2025 earnings estimate has been revised upward by $0.27 to $0.96 per share [9][10] - Interface, Inc. (TILE) is the world's largest manufacturer of modular carpets, holding a Zacks Rank of 2 and a VGM Score of A, with its 2025 earnings estimate revised to $1.58 per share [10][11] - Catalyst Pharmaceuticals, Inc. (CPRX) focuses on therapies for rare diseases, carrying a Zacks Rank of 2 and a VGM Score of A, with a recent upward revision of its 2025 earnings estimate to $2.25 per share [11][12] - Sterling Infrastructure, Inc. (STRL) operates in E-Infrastructure and Building Solutions, holding a Zacks Rank of 2 and a VGM Score of B, with its 2025 earnings estimate revised upward by $0.11 to $8.56 per share [13][14]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news, publications, and personal analysis intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].

Company Performance - Catalyst Pharmaceutical (CPRX) shares have increased by 8.4% over the past month and reached a new 52-week high of $26.58 [1] - The stock has gained 23.8% since the beginning of the year, outperforming the Zacks Medical sector, which declined by 3.5%, and the Zacks Medical - Drugs industry, which returned 4% [1] Earnings and Revenue - Catalyst has consistently exceeded earnings expectations, reporting EPS of $0.68 against a consensus estimate of $0.53 in its last earnings report on May 7, 2025, and beating revenue estimates by 8.92% [2] - For the current fiscal year, Catalyst is projected to achieve earnings of $2.24 per share on revenues of $559.96 million, reflecting a 1.81% increase in EPS and a 13.87% increase in revenues [3] - The next fiscal year forecasts earnings of $2.61 per share on revenues of $631.85 million, indicating year-over-year changes of 16.33% in EPS and 12.84% in revenues [3] Valuation Metrics - Catalyst's current valuation metrics show it trading at 11.5X current fiscal year EPS estimates, below the peer industry average of 16.9X, and at 10.6X trailing cash flow compared to the peer group's average of 11.6X [7] - The stock has a PEG ratio of 1.01, which does not place it among the top value stocks [7] Zacks Rank and Style Scores - Catalyst holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts, meeting the criteria for potential investment [8] - The stock has a Value Score of B, a Growth Score of B, and a Momentum Score of C, resulting in a combined VGM Score of A [6] Industry Comparison - AMNEAL PHARMACEUTICALS, INC. (AMRX) is a notable peer with a Zacks Rank of 2 (Buy) and strong earnings performance, having beaten consensus estimates by 40% last quarter [9][10] - The Medical - Drugs industry is positioned in the top 34% of all industries, suggesting positive market conditions for both CPRX and AMRX [11]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Catalyst Pharmaceutical (CPRX) - Catalyst Pharmaceutical currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance in the market [3] Price Performance - CPRX shares have increased by 1.92% over the past week, while the Zacks Medical - Drugs industry remained flat [5] - Over the past month, CPRX's price change is 8.02%, outperforming the industry's 3.76% [5] - In the last quarter, shares of CPRX have risen by 18.84%, and over the past year, they have gained 55.3%, compared to the S&P 500's increases of 2.37% and 14.4%, respectively [6] Trading Volume - The average 20-day trading volume for CPRX is 1,094,588 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, four earnings estimates for CPRX have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from $2.15 to $2.25 [9] - For the next fiscal year, three estimates have moved up, while one has been revised down [9] Conclusion - Considering the strong momentum indicators and positive earnings outlook, CPRX is identified as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [11]

Core Insights - Investors in the Medical - Drugs sector may find Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX) to be potential investment opportunities, with a need to evaluate which stock is more appealing for value investors [1] Valuation Metrics - CPRX has a forward P/E ratio of 11.09, significantly lower than NBIX's forward P/E of 32.88, indicating that CPRX may be undervalued [5] - The PEG ratio for CPRX is 0.98, while NBIX has a PEG ratio of 1.28, suggesting that CPRX offers better value relative to its expected earnings growth [5] - CPRX's P/B ratio stands at 3.82 compared to NBIX's P/B of 4.86, further supporting the notion that CPRX is more attractively valued [6] Zacks Rank and Earnings Outlook - Currently, CPRX holds a Zacks Rank of 2 (Buy), while NBIX has a Zacks Rank of 3 (Hold), indicating a more favorable earnings outlook for CPRX [3] - The positive revisions in earnings estimates for CPRX suggest an improving earnings outlook, which is a critical factor for value investors [3][7] Value Grades - CPRX has received a Value grade of A, while NBIX has a Value grade of C, reflecting the stronger valuation metrics and estimate revision activity for CPRX [6][7]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

Group 1 - Catalyst Pharmaceutical (CPRX) closed at $24.96, with a 0.5% gain over the past four weeks, and a mean price target of $34 indicates a 36.2% upside potential [1] - The average price targets range from a low of $31 to a high of $40, with a standard deviation of $2.98, suggesting a 24.2% to 60.3% upside potential [2] - Analysts show strong agreement on CPRX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 3.5% over the last 30 days, with four estimates moving higher and no negative revisions [12] - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide [13]

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of a trend in short-term investing, highlighting that successful entry timing is crucial for capitalizing on price movements [1][2]. Group 1: Trend Analysis - The trend can reverse before exiting a trade, potentially leading to short-term capital losses for investors [2]. - A stock's recent price strength is a key indicator of its potential to maintain upward momentum, with a focus on stocks trading in the upper portion of their 52-week high-low range [3][5]. Group 2: Company Spotlight - Catalyst Pharmaceutical (CPRX) - Catalyst Pharmaceutical (CPRX) has shown a solid price increase of 13.7% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - CPRX has maintained a price increase of 0.5% over the past four weeks, suggesting that the upward trend is still intact [5]. - The stock is currently trading at 89.5% of its 52-week high-low range, indicating a potential breakout [5]. Group 3: Fundamental Strength - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The Zacks Rank system has a strong historical performance, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988 [7]. - The Average Broker Recommendation for CPRX is 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 4: Investment Strategy - The article suggests that CPRX may continue its price trend without reversal in the near future, and encourages exploring other stocks that meet similar criteria [8]. - Investors are advised to utilize various Zacks Premium Screens to identify potential winning stock picks based on their investment style [8].

Core Insights - Catalyst Pharmaceuticals announced the appointment of Dr. William T. Andrews as Chief Medical Officer, succeeding Dr. Gary Ingenito, who is retiring after a successful career [1][4] - Dr. Andrews brings 24 years of global biopharmaceutical experience, particularly in rare diseases, and has held leadership roles in various biopharmaceutical organizations [2][3] - Catalyst is recognized for its strong financial performance and commitment to improving the lives of patients with rare diseases, focusing on innovative therapies and expanding its global presence [5] Company Overview - Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases, with a strong emphasis on patient care and accessibility [5] - The company has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies [5]

Group 1 - The article emphasizes that investing is a learning process, where failures serve as tuition and successes contribute to lessons learned [1] - The author has approximately five years of focused research on various stocks, with a primary emphasis on healthcare stocks in recent years [1] Group 2 - There is no current stock, option, or similar derivative position in any of the companies mentioned, but there may be plans to initiate a beneficial long position within the next 72 hours [2] - The article expresses the author's own opinions and is not influenced by any business relationships with the companies mentioned [2]